Literature DB >> 6770675

Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.

S S Raghavan, J Topol, E H Kolodny.   

Abstract

Human leukocytes contain at least two isozymes of 4-methylumbelliferyl-beta-glucosidase acting optimally at pH 4.0 and 4.8; in Gaucher disease, only the former is deficient. Brief exposure of the leukocyte homogenate to pH 4.0 at room temperature results in irreversible inactivation of the pH 4.8 activity, while the activity at pH 4.0 remains unaffected. The more acidic isozyme is stimulated four- to fivefold by 0.2% sodium taurodeoxycholate (TDC) with a shift in the pH optimum to 5.0. The less acidic isozyme is completely suppressed in the presence of this detergent. Both leukocyte isozymes appear to be membrane-bound since gel filtration of Sephadex G-200 produces only one peak of activity located at the void volume, unlike in liver and kidney where a second peak also can be demonstrated. Heat inactivation analysis indicated that in controls, assayed in the absence of detergent, pH 4.0 activity is more thermostable than pH 4.8 activity. However, in Gaucher disease, the residual beta-glucosidase at pH 4.0 is just as thermolabile as the unaffected pH 4.8 activity. Heat inactivation of the enzyme in the presence of TDC resulted in rapid loss of activity, suggesting a direct effect of the bile salt on the configuration of the enzyme decreasing its thermal stability. In the absence of detergent, acid beta-glucosidase shows two K(m)'s, one at 3.2 mM and another at 0.9 mM. In the presence of detergent, only the higher K(m) at 3.3 mM is obtained. In patients with Gaucher disease and in obligate carriers, the K(m) remains essentially unaffected while the V(max) shows the expected deficiency.A reliable and reproducible selective assay technique has been developed for the diagnosis of Gaucher disease homozygotes and obligate heterozygotes and for the carrier screening of individuals at risk for this inherited disorder. The efficacy of this technique has been demonstrated by studying the activity in 42 controls, 26 patients, 32 obligate heterozygotes, and 23 healthy relatives of patients with Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770675      PMCID: PMC1686022     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  29 in total

1.  Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes.

Authors:  E Beutler; W Kuhl
Journal:  Lancet       Date:  1970-03-21       Impact factor: 79.321

2.  Cystic fibrosis and liver -galactosidase and -glucosidase.

Authors:  J Butterworth; A D Bain; W M McCrae
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

3.  Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid beta-glucosidase in cultured fibroblasts.

Authors:  M W Ho; J Seck; D Schmidt; M L Veath; W Johnson; R O Brady; J S O'Brien
Journal:  Am J Hum Genet       Date:  1972-01       Impact factor: 11.025

4.  Identity of beta-glucosidase, beta-xylosidase and one of the beta-galactosidase activities in human liver when assayed with 4-methylumbelliferyl-beta-D-glycosides studies in cases of Gaucher's disease.

Authors:  P A Ockerman
Journal:  Biochim Biophys Acta       Date:  1968-08-06

5.  Beta-glucosidase activities in human tissues. Findings in Gaucher's disease.

Authors:  B Hultberg; P A Ockerman
Journal:  Clin Chim Acta       Date:  1970-04       Impact factor: 3.786

6.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

Authors:  R O Brady; J N Kanfer; R M Bradley; D Shapiro
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

7.  Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro.

Authors:  M W Ho; J S O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

8.  Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher's disease.

Authors:  E Beutler; W Kuhl; F Trinidad; R Teplitz; H Nadler
Journal:  Am J Hum Genet       Date:  1971-01       Impact factor: 11.025

9.  The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes.

Authors:  E Beutler; W Kuhl
Journal:  J Lab Clin Med       Date:  1970-11

10.  Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood.

Authors:  J P Kampine; R O Brady; J N Kanfer; M Feld; D Shapiro
Journal:  Science       Date:  1967-01-06       Impact factor: 47.728

View more
  27 in total

1.  Cerebroside-beta-glucosidase encapsulation in liposomes for Gaucher's disease treatment revisited.

Authors:  V Korablyov; A Zimran; Y Barenholz
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  G(M2)-ganglioside metabolism in situ in mucolipidosis IV fibroblasts.

Authors:  S Raghavan; E Leshinsky; E H Kolodny
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

3.  Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.

Authors:  Anu R Sawkar; Wei-Chieh Cheng; Ernest Beutler; Chi-Huey Wong; William E Balch; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

4.  Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.

Authors:  Roberto A Ortega; Paola A Torres; Matthew Swan; William Nichols; Sarah Boschung; Deborah Raymond; Matthew J Barrett; Brooke A Johannes; Lawrence Severt; Vicki Shanker; Ann L Hunt; Susan Bressman; Gregory M Pastores; Rachel Saunders-Pullman
Journal:  J Clin Neurosci       Date:  2016-02-05       Impact factor: 1.961

5.  Type 2 Gaucher disease in an infant despite a normal maternal glucocerebrosidase gene.

Authors:  Ermias Hagege; Richard J Grey; Grisel Lopez; Tamanna Roshan Lal; Ellen Sidransky; Nahid Tayebi
Journal:  Am J Med Genet A       Date:  2017-11-01       Impact factor: 2.802

6.  Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.

Authors:  E I Ginns; R O Brady; S Pirruccello; C Moore; S Sorrell; F S Furbish; G J Murray; J Tager; J A Barranger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

7.  Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.

Authors:  Y Sato; E Beutler
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  The human glucocerebrosidase gene has two functional ATG initiator codons.

Authors:  J A Sorge; C West; W Kuhl; L Treger; E Beutler
Journal:  Am J Hum Genet       Date:  1987-12       Impact factor: 11.025

9.  Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer.

Authors:  J Sorge; W Kuhl; C West; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

10.  Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages.

Authors:  E Beutler; W Kuhl; L M Vaughan
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.